Capsugel expands plants in U.S., EU; Recipharm to manufacture Abstral; India's USV faces FDA issues;

@EricPFierce: After sales of Bydureon came up short, Bristol-Myers, AstraZeneca report manufacturing has too. Article | Follow @EricPFierce

> Capsugel says it is expanding plants in the U.S., U.K. and France that make finished dosage products. Release

> Recipharm Stockholm will manufacture the sublingual tablet Abstral for Kyowa Hakko Kirin after it received approval for use in Japan. Release

> The FDA will require a color change on the writing on Duragesic pain patches to help prevent deaths from accidental exposure to fentanyl patches. Announcement

> Catalent has partnered with Supernus Pharmaceuticals ($SUPN) to supply the drugmaker's extended-release epilepsy drug. Story

> A Nigerian official pledges that the country will prosecute drug counterfeiters. Report

> The Economic Times says it has seen a Form 483 for the laboratory of Indian-based USV saying it had falsified data on drug weights. Report

And Finally... Drugmakers are urging the FDA to provide more clarity on its guidance concerning quality agreements with contract manufacturers. Story

Launch Readiness

Optimize cross-functional collaboration and engage with key stakeholders for the successful launch of a product

Join the Launch Readiness for Medical Affairs & Communications Teams Summit to learn best practices in taking a structured approach to enhance medical affairs activities surrounding a launch and increase knowledge and communication with thought leaders.